Story
Babcock International Stock Gains After Reaffirming Full-Year Guidance

Summary
Shares in the UK defense contractor rose after the company confirmed its fiscal 2027 financial targets at its Annual General Meeting, citing trading in line with expectations.
Shares of Babcock International (LSE:BAB) climbed 2.0% to 1,013p in recent trading after the defense and engineering group reaffirmed its full-year guidance for fiscal 2027 at its Annual General Meeting in London.
Guidance and Performance
Babcock's management told investors that trading across its marine, nuclear, and land divisions during the first five months of the fiscal year has been consistent with its expectations. The company maintained its outlook for the full fiscal year 2027, for which analysts forecast revenue of approximately £5.49 billion and an underlying operating profit of £464 million.
These projections represent a significant increase from the prior year's results, which saw revenues of £5.19 billion and an underlying operating profit of £293 million, according to Investing.com.
Capital Returns and Company Targets
The positive outlook is supported by the company's ongoing execution of a £200 million share buyback programme. Babcock has already acquired more than 14 million shares to be held in treasury, a move that signals management’s confidence that the stock is undervalued.
AdThis capital return initiative aligns with Babcock's medium-term financial targets, which include:
- Mid-single-digit organic revenue growth
- An underlying operating margin of at least 9%
Market Context
As a FTSE 100 constituent, Babcock is well-positioned to benefit from structural tailwinds in the defense sector, particularly sustained military and nuclear infrastructure investment among NATO allies. This environment supports the company's long-term order visibility and contract backlog.
Despite the day's gains, the stock remains significantly below its 52-week high of 1,527p. The reaffirmation of guidance, combined with the active share repurchase plan, provided investors with renewed confidence in the company's trajectory.
Read next
More on Stocks
Electra Therapeutics IPO Poised to Price Above Midpoint on Strong Investor Demand
The biotechnology company is expected to price its initial public offering in the upper half of its $14 to $16 range, following significant interest from institutional investors, according to reports.

Vicor Shares Surge 15%, But Record Put Volume Signals Investor Caution
Shares of Vicor Corporation rallied over 15% on Thursday, yet options market data revealed a record volume of put contracts, suggesting some investors are betting against the sustainability of the surge.

Generac Stock Surges, Options Buzz After Securing Amazon as Data Center Client
Generac Holdings announced a multi-billion dollar agreement to supply industrial generators to Amazon's data centers, causing its stock to rally and igniting significant short-term options trading.

Moroccan All Shares Index Slips to One-Month Low on Banking, Mining Weakness
Morocco's main stock index, the Moroccan All Shares, closed down 0.17% on Thursday, hitting its lowest point in a month. The decline was primarily driven by losses in the banking, mining, and utilities sectors.